| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
HeLa cells were resistant to CD4-independent HIV infection. We identified cystatin-C (cathepsin protease inhibitor) that conferred HeLa cells susceptible to CD4-independent HIV infection. When target cells were treated with a low molecular weight cathepsin inhibitor, CA-074Me, CD4-independent HIV infection was enhanced. Because CD4-independent HIV infection was attenuated by an endocytosis inhibitor, the infection occurs through endosomes. When cathepsin activity is relatively higher, CD4-independent HIV infectivity may be reduced due to the degradation of HIV particlesincorporated into endosomes by cathepsin. Although murine leukemia virus (MLV) infection occurs via endosomes, MLV infection was rather suppressed by CA-074Me. This result indicates that cathepsin is required for MLV infection unlike CD4-independent HIV infection. Because MLV infection in XC cells is not suppressed by endosome acidificationinhibitors, it is widely accepted that MLV infection does not occur via endosomes specifically in XC cells. We found that MLV infection in XC cells occurs through endosomes, and cathepsin activated without endosome acidification in XC cells confers MLV infection resistant to endosome acidification inhibitors.
|
